Product Description
Droxidopa is used to treat symptoms (dizziness, lightheadedness, or a fainting sensation [feeling that you are about to black out]) of neurogenic orthostatic hypotension (a sudden fall in blood pressure that occurs when a person assumes a standing position caused by certain nervous system conditions). Droxidopa is in a class of medications called alpha and beta-adrenergic agonists. It works by increasing the levels of norepinephrine, a natural substance in the body. (Sourced from: https://medlineplus.gov/druginfo/meds/a614025.html)
Mechanisms of Action: DDC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Egypt | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/11/2025 |
News Article |
Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments |
|
04/10/2025 |
News Article |
CivicaScript® Launches Treatment for Symptomatic Neurogenic Orthostatic Hypotension to Drive Savings for Patients, Healthcare System |
|
11/17/2023 |
News Article |
Virpax Pharmaceuticals Announces Leadership Transition |
|
10/10/2023 |
News Article |
Menkes Syndrome Market Size, Share and Forecast 2031 |